Cellosaurus logo
expasy logo

Cellosaurus SK-OV-3 (CVCL_0532)

[Text version]
Cell line name SK-OV-3
Synonyms SKOV-3; SK-OV3; SK.OV.3; SKOV3; Skov3; SKO3; SKOV3 (S)
Accession CVCL_0532
Resource Identification Initiative To cite this cell line use: SK-OV-3 (RRID:CVCL_0532)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: JFCR39 cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI-60 cancer cell line panel.
Part of: OCCP ovarian cancer cell line panel.
From: Memorial Sloan Kettering Cancer Center; New York; USA.
Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-528.
Population: Caucasian.
Doubling time: 44 hours (PubMed=7718330); 19 hours (PubMed=2653399); 28 +- 2 hours (PubMed=3804493); 28.8 hours (PubMed=4016745); 75 hours (PubMed=25984343); 48.7 hours (NCI-DTP=SK-OV-3); ~35 hours (PBCF); 33.29 hours (GrayJW panel).
Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Exosome proteome analysis.
Omics: Fluorescence phenotype profiling.
Omics: Genome sequenced.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Misspelling: SCOV-3; Note=Occasionally.
Misspelling: SCOV3; Note=Occasionally.
Misspelling: SKVO3; Note=Occasionally.
Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
Sequence variations
HLA typing Source: PubMed=15748285
Class I
HLA-AA*03,68
HLA-BB*18,35
HLA-CC*04,05
Class II
HLA-DPDPB1*02:01:02,04:01
HLA-DQDQB1*02:01,05:01:01
HLA-DRDRB1*01,03:01:01

Source: PubMed=26589293
Class I
HLA-AA*03:01,68:01
HLA-BB*18:01,35:01
HLA-CC*04:01,05:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African1.52
Native American0
East Asian, North1.76
East Asian, South0
South Asian1.14
European, North59.05
European, South36.53
Disease Ovarian serous cystadenocarcinoma (NCIt: C7978)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_F642 (IST-1 [Human contaminated placenta])CVCL_YJ94 (LINTERNA SK-OV-3)CVCL_XB82 (SK-OV-3-Cas9-560)
CVCL_XB83 (SK-OV-3-Cas9-561)CVCL_XB84 (SK-OV-3-Cas9-562)CVCL_XB85 (SK-OV-3-Cas9-563)
CVCL_XB86 (SK-OV-3-Cas9-564)CVCL_YU10 (SK-OV-3-hCD271)CVCL_4Y20 (SK-OV-3-Luc)
CVCL_C9F9 (SK-OV-3/Cas9-hyg)CVCL_D621 (SK-OV-3/CBP)CVCL_D622 (SK-OV-3/CDDP)
CVCL_4Y19 (SK-OV-3/CMV-Luc)CVCL_ZZ42 (SKOV-3/BCRP)CVCL_JY94 (SKOV-3/GFP-Luc)
CVCL_M089 (SKOV-3/Luc)CVCL_M090 (SKOV-3/RFP)CVCL_4V89 (SKOV-3TR)
CVCL_C8XP (SKOV3 (R))CVCL_VS41 (SKOV3-A2)CVCL_UI88 (SKOV3-CisR)
CVCL_C3C2 (SKOV3-GFP-HER2)CVCL_C3C1 (SKOV3-GFP-STAT3)CVCL_5J38 (SKOV3-luc-D3)
CVCL_5J11 (SKOV3-Red-FLuc)CVCL_B0WE (SKOV3-TAX/CBP)CVCL_0C84 (SKOV3.ip1)
CVCL_B3Q0 (SKOV3/MRP7)CVCL_HF69 (SKOV3/TR)CVCL_Y280 (SKOV3/VP)
CVCL_XB81 (SKOV3/VP16)CVCL_IN06 (SKVCR0.015)CVCL_IN07 (SKVCR0.1)
CVCL_IN08 (SKVCR0.25)CVCL_IN09 (SKVCR2.0)CVCL_IN03 (SKVLB0.03)
CVCL_IN04 (SKVLB0.06)CVCL_IN05 (SKVLB1)
Sex of cell Female
Age at sampling 64Y
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; KCLB; PubMed=11416159; PubMed=19372543; PubMed=25230021; PubMed=25877200; PubMed=30485824

Markers:
AmelogeninX
CSF1PO11
D2S133818,23
D3S135813,14 (PubMed=19372543)
14 (CCRID; CLS; PubMed=25230021; PubMed=25877200)
D5S81811
D7S82013,14
D8S117914,15
D13S3178,11
D16S53912
D18S5116,17 (PubMed=19372543; PubMed=25230021_ECACC_version; PubMed=25877200)
16,17,18 (CCRID; CLS; PubMed=11416159)
16,18 (PubMed=25230021_academic_lab_version)
D19S43314,14.2
D21S1130,31,31.2 (CLS; PubMed=11416159; PubMed=30485824)
30,31.2 (CCRID; PubMed=19372543; PubMed=25230021; PubMed=25877200)
FGA23,24,25 (PubMed=25230021_ECACC_version)
24,25 (CCRID; KCLB; PubMed=25230021_academic_lab_version; PubMed=25877200)
24,25,26 (CLS; PubMed=11416159)
Penta D12,13
Penta E5,13
TH019,9.3
TPOX8,11
vWA17 (PubMed=25230021_academic_lab_version)
17,18 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; KCLB; PubMed=11416159; PubMed=25230021_ECACC_version; PubMed=25877200; PubMed=30485824)
18 (PubMed=19372543)

Run an STR similarity search on this cell line
Web pages https://en.wikipedia.org/wiki/SK-OV-3
https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://www.synapse.org/#!Synapse:syn31544449
https://strap.nci.nih.gov/celline_detail.php?sample_id=27
http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=SK-OV-3
https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/s/cell-lines-detail-19.html
https://www.mskcc.org/research-advantage/support/technology/tangible-material/human-ovarian-cell-line-sk-ov-3
https://tcpaportal.org/mclp/
Publications

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=4016745
Buick R.N., Pullano R., Trent J.M.
Comparative properties of five human ovarian adenocarcinoma cell lines.
Cancer Res. 45:3668-3676(1985)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3804493; DOI=10.1002/ijc.2910390216
Hill B.T., Whelan R.D.H., Gibby E.M., Sheer D., Hosking L.K., Shellard S.A., Rupniak H.T.
Establishment and characterisation of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies.
Int. J. Cancer 39:219-225(1987)

PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=2653399; DOI=10.1038/bjc.1989.108
Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P., Harrap K.R.
Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
Br. J. Cancer 59:527-534(1989)

PubMed=1892748; DOI=10.1038/bjc.1991.279
Mistry P., Kelland L.R., Abel G., Sidhar S., Harrap K.R.
The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
Br. J. Cancer 64:215-220(1991)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=1423261
Mistry P., Kelland L.R., Loh S.Y., Abel G., Murrer B.A., Harrap K.R.
Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Cancer Res. 52:6188-6193(1992)

PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H
Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J., McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M., van Zijl P.
Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.
Eur. J. Cancer 31:230-237(1995)

PubMed=8557231; DOI=10.1006/gyno.1996.0014
Skilling J.S., Squatrito R.C., Connor J.P., Niemann T., Buller R.E.
p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines.
Gynecol. Oncol. 60:72-80(1996)

PubMed=9041185
Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
Cancer Res. 57:850-856(1997)

PubMed=9554442; DOI=10.1093/jnci/90.8.597
Sabichi A.L., Hendricks D.T., Bober M.A., Birrer M.J.
Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide.
J. Natl. Cancer Inst. 90:597-605(1998)

PubMed=9698466; DOI=10.1006/gyno.1998.5039
Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C., Berchuck A., Futreal P.A.
Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
Gynecol. Oncol. 70:13-16(1998)

PubMed=10318951; DOI=10.1073/pnas.96.10.5722
Lau K.-M., Mok S.C., Ho S.-M.
Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.
Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H
Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Mol. Carcinog. 28:236-246(2000)

PubMed=11416159; DOI=10.1073/pnas.121616198
Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=11565033; DOI=10.1038/35095068
Moberg K.H., Bell D.W., Wahrer D.C.R., Haber D.A., Hariharan I.K.
Archipelago regulates cyclin E levels in Drosophila and is mutated in human cancer cell lines.
Nature 413:311-316(2001)

PubMed=11789735; DOI=10.1309/4NCM-QJ9W-QM0J-6QJE
Rhodes A., Jasani B., Couturier J., McKinley M.J., Morgan J.M., Dodson A.R., Navabi H., Miller K.D., Balaton A.J.
A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.
Am. J. Clin. Pathol. 117:81-89(2002)

PubMed=11793438; DOI=10.1002/gcc.1221
Rao P.H., Harris C.P., Lu X.-Y., Li X.-N., Mok S.C., Lau C.C.
Multicolor spectral karyotyping of serous ovarian adenocarcinoma.
Genes Chromosomes Cancer 33:123-132(2002)

PubMed=12080474; DOI=10.1038/sj.onc.1205542
Manzano R.G., Montuenga L.M., Dayton M., Dent P., Kinoshita I., Vicent S., Gardner G.J., Nguyen P., Choi Y.-H., Trepel J., Auersperg N., Birrer M.J.
CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential.
Oncogene 21:4435-4447(2002)

PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x
Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M., Takayama M., Sato A., Inazawa J.
Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.
Jpn. J. Cancer Res. 93:1114-1122(2002)

PubMed=12960427; DOI=10.1091/mbc.E03-05-0279
Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G., Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H., Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J., Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R., van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O., Sikic B.I.
Gene expression patterns in ovarian carcinomas.
Mol. Biol. Cell 14:4376-4386(2003)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)

PubMed=16380993; DOI=10.1002/ijc.21671
Huang K.-C., Park D.C., Ng S.-K., Lee J.Y., Ni X.-Y., Ng W.-C., Bandera C.A., Welch W.R., Berkowitz R.S., Mok S.C., Ng S.-W.
Selenium binding protein 1 in ovarian cancer.
Int. J. Cancer 118:2433-2440(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17726699; DOI=10.1002/gcc.20492
Buys T.P.H., Chari R., Lee E.H.-L., Zhang M., MacAulay C., Lam S., Lam W.L., Ling V.
Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells.
Genes Chromosomes Cancer 46:1069-1079(2007)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20204287; DOI=10.3892/or_00000728
Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H., Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.
Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.
Oncol. Rep. 23:1021-1026(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=21912889; DOI=10.1007/s10637-011-9744-z
Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A., Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P., Ding A., Baguley B.C.
Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.
Invest. New Drugs 30:2035-2045(2012)

PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170
Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D., Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B., Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A., Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.
Genomic complexity and AKT dependence in serous ovarian cancer.
Cancer Discov. 2:56-67(2012)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D.-X., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=22705003; DOI=10.1016/j.humpath.2012.03.011
Rahman M., Nakayama K., Rahman M.T., Nakayama N., Ishikawa M., Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih I.-M., Miyazaki K.
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Hum. Pathol. 43:2197-2206(2012)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=23839242; DOI=10.1038/ncomms3126
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Evaluating cell lines as tumour models by comparison of genomic profiles.
Nat. Commun. 4:2126.1-2126.10(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24023729; DOI=10.1371/journal.pone.0072162
Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
Type-specific cell line models for type-specific ovarian cancer research.
PLoS ONE 8:E72162-E72162(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013)

PubMed=24434149; DOI=10.1016/j.bbrc.2013.12.070
Sinha A., Ignatchenko V., Ignatchenko A., Mejia-Guerrero S., Kislinger T.
In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome.
Biochem. Biophys. Res. Commun. 445:694-701(2014)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25230021; DOI=10.1371/journal.pone.0103988
Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
PLoS ONE 9:E103988-E103988(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25846456; DOI=10.3892/ijo.2015.2951
Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M., Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.
Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Int. J. Oncol. 46:2389-2398(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26169745; DOI=10.1186/s12967-015-0576-z
Halama A., Guerrouahen B.S., Pasquier J., Diboun I., Karoly E.D., Suhre K., Rafii A.
Metabolic signatures differentiate ovarian from colon cancer cell lines.
J. Transl. Med. 13:223.1-223.12(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=26668597; DOI=10.3892/etm.2015.2836
Ruan Z.-Y., Liu J.-H., Kuang Y.-P.
Isolation and characterization of side population cells from the human ovarian cancer cell line SK-OV-3.
Exp. Ther. Med. 10:2071-2078(2015)

PubMed=26925792; DOI=10.4149/315_150930N510
Saczko J., Pilat J., Choromanska A., Rembialkowska N., Bar J.K., Kaminska I., Zalewski J., Kulbacka J.
The effectiveness of chemotherapy and electrochemotherapy on ovarian cell lines in vitro.
Neoplasma 63:450-455(2016)

PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028
Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F., Noonan A.M., Annunziata C.M.
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
Gynecol. Oncol. 142:332-340(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028
Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A., Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J., Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.
Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.
Cell Rep. 18:2343-2358(2017)

PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096
Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J., Velculescu V.E., Scharpf R.B.
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Cell Rep. 25:2617-2633(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=32612269; DOI=10.1038/s41598-020-67533-1
De Haven Brandon A., Box G., Hallsworth A., Court W., Matthews N., Herodek B., Arteagabeitia A.B., Valenti M., Kirkin V.
Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.
Sci. Rep. 10:10799-10799(2020)

PubMed=33519462; DOI=10.3389/fphar.2020.600994
Zhang Y.-Q., Gan H.-Y., Zhao F., Ma X.-M., Xie X.-F., Huang R., Zhao J.
CPEB4-promoted paclitaxel resistance in ovarian cancer in vitro relies on translational regulation of CSAG2.
Front. Pharmacol. 11:600994.1-600994.10(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) AddexBio; C0017008/5024
ATCC; HTB-77
CCTCC; GDC0114
CLS; 300342
ECACC; 91091004
ICLC; HTL01014 - Discontinued
IZSLER; BS TCL 84
KCB; KCB 200810YJ
KCLB; 30077
NCBI_Iran; C209
NCI-DTP; SK-OV-3
Cell line databases/resources CLO; CLO_0009063
MCCL; MCC:0000431
CLDB; cl4354
CLDB; cl4355
CLDB; cl4356
cancercelllines; CVCL_0532
CCRID; 1101HUM-PUMC000027
CCRID; 3101HUMTCHu185
CCRID; 4201HUM-CCTCC00114
Cell_Model_Passport; SIDM00079
Cosmic-CLP; 905959
DepMap; ACH-000811
IGRhCellID; SKOV3
LINCS_HMS; 50044
LINCS_LDP; LCL-1517
Lonza; 133
SKY/M-FISH/CGH; 1438
Anatomy/cell type resources BTO; BTO:0000948
Biological sample resources BioSample; SAMN03471310
BioSample; SAMN05292466
BioSample; SAMN10987874
CRISP screens repositories BioGRID_ORCS_Cell_line; 372
Chemistry resources ChEMBL-Cells; CHEMBL3307746
ChEMBL-Targets; CHEMBL614925
GDSC; 905959
PharmacoDB; SKOV3_1411_2019
PubChem_Cell_line; CVCL_0532
Encyclopedic resources Wikidata; Q50432263
Experimental variables resources EFO; EFO_0002340
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM2110
GEO; GSM50223
GEO; GSM50287
GEO; GSM183338
GEO; GSM183341
GEO; GSM274701
GEO; GSM313702
GEO; GSM459638
GEO; GSM459643
GEO; GSM459644
GEO; GSM459645
GEO; GSM659405
GEO; GSM711713
GEO; GSM743478
GEO; GSM743500
GEO; GSM750833
GEO; GSM784565
GEO; GSM799368
GEO; GSM799431
GEO; GSM827322
GEO; GSM847159
GEO; GSM851940
GEO; GSM887598
GEO; GSM888681
GEO; GSM1001423
GEO; GSM1001424
GEO; GSM1001486
GEO; GSM1153439
GEO; GSM1181272
GEO; GSM1181301
GEO; GSM1291150
GEO; GSM1340593
GEO; GSM1374883
GEO; GSM1670455
GEO; GSM2124684
GEO; GSM2475005
Polymorphism and mutation databases Cosmic; 687925
Cosmic; 688110
Cosmic; 755846
Cosmic; 809115
Cosmic; 844348
Cosmic; 849611
Cosmic; 875858
Cosmic; 897436
Cosmic; 897739
Cosmic; 905959
Cosmic; 906578
Cosmic; 920359
Cosmic; 923106
Cosmic; 924150
Cosmic; 927563
Cosmic; 932983
Cosmic; 947358
Cosmic; 948289
Cosmic; 949228
Cosmic; 991320
Cosmic; 1044243
Cosmic; 1057759
Cosmic; 1066218
Cosmic; 1070900
Cosmic; 1071897
Cosmic; 1092635
Cosmic; 1093556
Cosmic; 1102817
Cosmic; 1113276
Cosmic; 1129658
Cosmic; 1139226
Cosmic; 1175886
Cosmic; 1176622
Cosmic; 1305333
Cosmic; 1312193
Cosmic; 1312359
Cosmic; 1436037
Cosmic; 1482526
Cosmic; 1523762
Cosmic; 1524361
Cosmic; 1707561
Cosmic; 1708388
Cosmic; 1709249
Cosmic; 1998478
Cosmic; 2301586
Cosmic; 2464670
Cosmic; 2560252
Cosmic; 2582807
Cosmic; 2668296
IARC_TP53; 21123
LiGeA; CCLE_824
Progenetix; CVCL_0532
Proteomic databases PRIDE; PXD001402
PRIDE; PXD005940
PRIDE; PXD005942
PRIDE; PXD005946
PRIDE; PXD007615
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number45